Advice
following an abbreviated submission:
ciclosporin (Vevizye®) is accepted for restricted use within NHSScotland.
Indication under review: treatment of moderate to severe dry eye disease (keratoconjunctivitis sicca) in adult patients, which has not improved despite treatment with tear substitutes.
SMC restriction: severe keratitis in adult patients with dry eye disease.
Vevizye® is a new formulation of ciclosporin eye drops, with limited net budget impact.
Download detailed advice298KB (PDF)
Medicine details
- Medicine name:
- ciclosporin (Vevizye)
- SMC ID:
- SMC2873
- Indication:
Treatment of moderate to severe dry eye disease (keratoconjuctivitis sicca) in adult patients, which has not improved despite treatment with tear substitutes.
- Pharmaceutical company
- Thea Pharmaceuticals
- BNF chapter
- Eye
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 19 January 2026